AS Watson: Pharma partner Icanthera’s cash reserves soar August 27, 2024 UK-based pharmaceutical company Icanthera said its cash reserves soared over the last year as it has struck a major deal and is focusing on developing new products. The company that manufactures dermatology and oncology treatments said its cash position increased to £61,000 at 31 March 2024, up from £3,000 in the previous year. Icanthera said [...]
GSK receives US breakthrough therapy designation for lung cancer treatment August 20, 2024 Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]
How Astrazeneca became the London Stock Exchange’s newest £200bn firm August 14, 2024 Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]
Hikma given shot in the arm by ‘excellent’ double-digit growth August 8, 2024 Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer August 6, 2024 GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.
GSK: Pharma giant raises guidance after second quarter sales give shot in the arm July 31, 2024 London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]
Astrazeneca shares fall after FTSE giant’s forecast lift fails to inspire July 25, 2024 In the first half of 2024, Astrazeneca reported an 18 per cent year-on-year increase in total revenue, reaching $2.6bn (£2bn).
Eco Animal Health beats expectations thanks to Americas growth July 15, 2024 Animal vaccine firm Eco Animal Health beat earnings expectations despite continuing volatility in currency, thanks largely to its "robust" demand for its flagship vaccine and consistent market leading position.
Indivior shares plunge after US move and profit warning July 9, 2024 Indivior lowered its annual adjusted operating profit forecast and shares in the company plunged.
British Patient Capital invests £90m London biotech company July 8, 2024 British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.